ahlam1399
08-20-2015, 06:29 PM
Lilly, Boehringer diabetes drug cuts heart attack, stroke risk in trial
(Reuters) - A new diabetes pill from Eli Lilly and Co and Boehringer Ingelheim cut risk of heart attack, stroke and death in a closely watched study, the first glucose-lowering drug to show such protective results in a large cardiovascular trial, the drugmakers said on Thursday.
http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4925eec1/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=vhgmafX-OY8:XTxS8DP8FUw:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=vhgmafX-OY8:XTxS8DP8FUw:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=vhgmafX-OY8:XTxS8DP8FUw:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=vhgmafX-OY8:XTxS8DP8FUw:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=vhgmafX-OY8:XTxS8DP8FUw:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/vhgmafX-OY8
(Reuters) - A new diabetes pill from Eli Lilly and Co and Boehringer Ingelheim cut risk of heart attack, stroke and death in a closely watched study, the first glucose-lowering drug to show such protective results in a large cardiovascular trial, the drugmakers said on Thursday.
http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4925eec1/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=vhgmafX-OY8:XTxS8DP8FUw:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=vhgmafX-OY8:XTxS8DP8FUw:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=vhgmafX-OY8:XTxS8DP8FUw:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=vhgmafX-OY8:XTxS8DP8FUw:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=vhgmafX-OY8:XTxS8DP8FUw:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/vhgmafX-OY8